Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... This drug is being explored as a potential groundbreaking disease-modifying therapy for osteoarthritis. LNA043 is part of Novartis’s early investigational efforts aimed at addressing cartilage damage and reducing inflammation associated with osteoarthritis. This drug, which ... Read More
-
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... of hyaluronic acid and plasma protein, substances naturally present in the synovial fluid of joints, along with a fast-acting analgesic. JTA-004 aims to improve joint lubrication, protect cartilage in osteoarthritic joints, and deliver effective pain ... Read More
-
North America RNA Therapeutics Market, By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Other Indications), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F
... User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F North America RNA Therapeutics Market was valued at USD 12.95 billion in 2023 and is anticipated to project robust growth ... Read More
-
Lab Instrumentation Markets for Pharmaceuticals & Biopharmaceuticals, 2024
... tackling complex cancers and rare diseases, the importance of this industry can’t be overstated. However, creating an ideal therapeutic is not a strait forward process. An illness must be identified, and an early stage of ... Read More
-
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... States and globally have demonstrated that INVOSSA can significantly relieve pain, improve mobility, and potentially slow osteoarthritis progression while enhancing joint structure. As an allogeneic, off-the-shelf therapy, it presents a promising alternative to traditional osteoarthritis ... Read More
-
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... supporting the normal function of damaged chondrocytes. This therapy for osteoarthritis also helps alleviate pain and maintain the normal structure of cartilage. By harnessing the regenerative power of stem cells, ELIXCYTE promotes tissue repair and ... Read More
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029
... global Life science analytics market is projected to reach USD 61.94 billion by 2029 from USD 35.69 billion in 2024, at a CAGR of 11.7% during the forecast period. The market is expected to grow ... Read More
-
Peptide Therapeutics
... at a CAGR of 4.2% over the analysis period 2023-2030. Liquid Phase Synthesis Technology, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$25.4 Billion by the ... Read More
-
Primary Immunodeficiency Therapeutics
... by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Antibody Deficiency Disease Type, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$8.5 ... Read More
-
Gout Therapeutics
... at a CAGR of 13.2% over the analysis period 2023-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$4.7 Billion by the end of the ... Read More
-
Immunosuppressants
... of 13.8% over the analysis period 2023-2030. Calcineurin Inhibitors, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$38.5 Billion by the end of the analysis period. ... Read More
-
Organs-on-Chips
... of 35.3% over the analysis period 2023-2030. Liver-on-Chip, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth ... Read More
-
Systemic Lupus Erythematosus (Sle) Drugs
... is expected to reach US$362.4 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. The U.S. Market is Estimated at US$63.3 Million While China is Forecast to Grow at 6.0% ... Read More
-
Nanosilver
... of 14.4% over the analysis period 2023-2030. Healthcare & Life Sciences End-Use, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Hypercalcemia Treatment
... at a CAGR of 9.3% over the analysis period 2023-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
MRSA Drugs
... at a CAGR of 4.4% over the analysis period 2023-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end ... Read More
-
Gynecological Cancer Drugs
... by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Cervical Cancer Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$10.3 Billion ... Read More
-
Compound Management
... at a CAGR of 16.9% over the analysis period 2023-2030. Compound Management Instruments, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$752.6 Million by the end ... Read More
-
Europe Next Generation Sequencing Market Report by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening, and Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Read Time Sequencing, Nanopore Sequencing, and Others), End-Users(Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), Country and Company Analysis 2024-2032
... Sequencing, Single-Molecule Read Time Sequencing, Nanopore Sequencing, and Others), End-Users(Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), Country and Company Analysis 2024-2032 Europe Next Generation Sequencing Market Outlooks Next ... Read More
-
Respiratory Syncytial Virus (RSV) Therapeutics
... Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2023-2030. Prophylaxis, one of the segments analyzed in the report, is expected to record a 28.5% CAGR and reach US$7.6 Billion by ... Read More
-
Male Infertility
... CAGR of 5.8% over the analysis period 2023-2030. DNA Fragmentation Technique, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Hunter Syndrome Treatment
... at a CAGR of 5.7% over the analysis period 2023-2030. Enzyme Replacement Therapy (ERT), one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$1.4 Billion by the ... Read More
-
Acute Coronary Syndrome - Market Insight, Epidemiology And Market Forecast - 2034
... US accounted for approximately 37% of the cases, EU4 and the UK countries accounted for around 54%, followed by Japan which represented nearly 9%. DelveInsight’s estimates indicate that in 2023, there were approximately 77,445 diagnosed ... Read More
-
Bronchiectasis - Market Insight, Epidemiology And Market Forecast - 2034
... the forecast period (2024–2034). This growth is primarily driven by rising diagnosed prevalent cases and the introduction of emerging therapies. According to DelveInsight's analysis, it is projected that approximately 41% of the Total Diagnosed Prevalent ... Read More
-
Chronic Heart Failure - Market Insight, Epidemiology And Market Forecast - 2034
... USD 12 billion which is further expected to rise at a CAGR of 2.8% by 2034. In 2023, the diagnosed prevalence of Atherosclerotic Cardiovascular Disease (ASCVD) was highest in the US among the 7MM, accounting ... Read More
Research Assistance
